(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of 42.05% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.49%.
Cytomx Therapeutics's revenue in 2026 is $18,302,000.On average, 9 Wall Street analysts forecast CTMX's revenue for 2026 to be $8,106,071,264, with the lowest CTMX revenue forecast at $2,199,475,373, and the highest CTMX revenue forecast at $18,303,539,856. On average, 9 Wall Street analysts forecast CTMX's revenue for 2027 to be $9,768,207,002, with the lowest CTMX revenue forecast at $4,270,825,966, and the highest CTMX revenue forecast at $19,378,872,823.
In 2028, CTMX is forecast to generate $11,429,689,043 in revenue, with the lowest revenue forecast at $4,270,825,966 and the highest revenue forecast at $19,378,872,823.